Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act

Micah Johnson; Rahul K Nayak; Lauren Gilstrap; Stacie B Dusetzina

doi:10.1001/jamacardio.2022.5033

Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act

JAMA Cardiol. 2023 Mar 1;8(3):299-301. doi: 10.1001/jamacardio.2022.5033.

Authors

Micah Johnson¹, Rahul K Nayak², Lauren Gilstrap³, Stacie B Dusetzina⁴

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
³ Dartmouth Hitchcock Medical Center, The Dartmouth Institute Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
⁴ Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.

No abstract available

Plain language summary

This cross-sectional study estimates out-of-pocket costs of heart failure with reduced ejection fraction medication regimens in Medicare Part D under current law and the Inflation Reduction Act.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Costs and Cost Analysis
Health Expenditures
Heart Failure* / drug therapy
Humans
Medicare Part D*
United States